JSMC
PRVB

Jess S. Morgan & Co’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Jess S. Morgan & Co’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-217,050
Closed -$2.28M – 44
2021
Q1 		$2.28M Buy
+217,050
New +$3.05M 1.6% 35

Other funds holding PRVB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Jess S. Morgan & Co's PRVB Position: Q2 2021 in Review

Jess S. Morgan & Co sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2021, closing a stake of 217,050 shares — an estimated $2.28M sold.

Jess S. Morgan & Co first reported a position in PRVB in Q1 2021 and held it in 1 quarter. The position peaked at $2.28M in Q1 2021. 125 funds tracked by Wall St. Rank hold PRVB as of Q2 2021.

  • Jess S. Morgan & Co reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Jess S. Morgan & Co sold 217,050 Provention Bio, Inc. Common Stock shares in Q2 2021, an estimated $2.28M.
  • Jess S. Morgan & Co first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Jess S. Morgan & Co's Provention Bio, Inc. Common Stock position peaked at $2.28M in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2021.

Based on Jess S. Morgan & Co's 13F filing for Q2 2021, filed 30 Nov 2021.